Invirsa, Inc.

COLUMBUS, OH · Founded 2016 · Biotech · Private

Small molecule therapeutic that enhances DNA damage response pathways

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · invirsa.com

Sector: Biotech
Headquarters: COLUMBUS, OH
Founded: 2016
Latest Form D: $2.8M, Aug 2025
Total capital: $57.8M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $9.8M; 4 Form D · last Aug 2025; 15 months since last filing
Federal contracts: $48M; 1 award · Health and Human S; Rank in Biotech#17 of 4373
Granted patents: 6; 12 pending · first 2021; Rank in peer group#245 of 1449

Capital timeline

Latest events

Aug 2025Private capital raisedForm D · SEC · 4th filing$2.8M
Nov 2023Private capital raisedForm D · SEC · 3rd filing$1.0M
Dec 2022Private capital raisedForm D · SEC · 2nd filing$6M
Dec 2020Private capital raisedForm D · SEC · 1st filing$40K
Sep 2020Federal contractHealth and Human S · INV-102 For The Treatment Of Mustard Gas Keratopathy Under BAA-18-100-SOL-00003, Area Of Interest 5.3.$48M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

2months

from Invirsa, Inc.’s first federal award to its first private round.

First federal award · Sep 2020: Health and Human S · $48M
First Form D · Dec 2020: $40K · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#245 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Robert ShalwitzResearcherExecutive Officer, DirectorLinked by 6 patents
Bethany GeorgeDirectorNamed in SEC Form D filings
Faith VoinovichDirectorNamed in SEC Form D filings
Michael VenerableDirectorNamed in SEC Form D filings
Rachael WingoExecutive OfficerNamed in SEC Form D filings
Samuel LeeDirectorNamed in SEC Form D filings

Show all 8 people

Tim WillisDirectorNamed in SEC Form D filings
Wayne EmbreeDirectorNamed in SEC Form D filings

What it has protected

USPTO · 6 granted of 18

Jul 29, 2025GrantedMethods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)USPTOUS 12,370,209
May 22, 2025PendingMethods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)USPTOApplication 19029481
Feb 25, 2025GrantedMethods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)USPTOUS 12,233,083

Show all 18 patent records

Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Jul 29, 2025 · US 12,370,209Granted
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)May 22, 2025 · Application 19029481Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Feb 25, 2025 · US 12,233,083Granted
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Jan 2, 2024 · US 11,857,561Granted
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Oct 24, 2023 · US 11,793,826Granted
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Sep 7, 2021 · US 11,110,112Granted
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Mar 16, 2021 · US 10,946,034Granted
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Application PCTUS2017018253Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Application 62428721Pending
Methods For Treating Adenovirus Related DiseasesApplication 62296665Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr) For Improving Visual AcuityApplication PCTUS2025048347Pending
Methods for the Use of 5'-Adenosine Diphosphate Ribose (ADPR) for VEGF ModulationApplication 19593229Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr) For Vegf ModulationApplication PCTUS2024058186Pending
Methods For The Use 5'-ADENOSINE Diphosphate Ribose (adpr) For Improving Visual AcuityApplication 63701208Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr) For Vegf ModulationApplication 63605852Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Application PCTUS2019023977Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Application 62693021Pending
Methods For The Use Of 5'-ADENOSINE Diphosphate Ribose (adpr)Application 62648585Pending

Cidara TherapeuticsSimilar federal contract value in Biotech · $58.1M in contracts
3D SystemsSimilar federal contract value in Biotech · $52.7M in contracts
Cempra PharmaceuticalsSimilar federal contract value in Biotech · $52.5M in contracts
OPHIREX, INCSimilar federal contract value in Biotech · $46.2M in contracts
METABOLON, INC.Similar federal contract value in Biotech · $42M in contracts
EITR BIOLOGICS, INC.Similar federal contract value in Biotech · $39.6M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.